Lytix Biopharma's second-quarter 2026 report was dominated by the FDA's feedback that it raises no objection to the design of a single regis...
Redeye comments on Lytix' first quarter report 2026.
Redeye is positive about the discovery of abscopal effects in non-treated lesions in basal cell carcinoma in Verrica's phase II study.
Redeye is optimistic about the full results from ATLAS-IT-05.
Redeye comments on Lytix' third quarter report 2025.
Redeye is optimistic about the directed share issue announced last week and a potential subsequent offering.
We raise our base case after having evaluated the financial situation of Verrica, which raised USD50m in November.
Redeye is bullish after the strong numbers from the NeoLIPA readout presented this morning.
Redeye provides a brief comment on Verrica's new results from the study in BCC.
Redeye comments on Lytix Biopharma’s Q2 report 2025 in an extended update.
Redeye comments on Lytix Biopharma’s first quarter review of 2025.
Redeye comments on Lytix Biopharma's Q4 report. During the quarter, Verrica reported further progress in basal cell carcinoma, the first pat...
Redeye comments on the successful directed share issue of NOK100m and EUR1m primary bid offering.
We have analised Verrica's funding and update our base case for Lytix based on Verrica's improved financial health.
Redeye comments on Lytix' Q3 report. The main event since our last update is the start of the NeoLIPA trial, a study of LTX-315 as neoadjuva...
Redeye comments on Lytix’ second quarter report 2024.
Yesterday, August 14, Verrica presented its top line results from the phase II study of LTX-315 in basal cell carcinoma with outstanding eff...
Redeye comments on the Q1 report 2024. The rest of 2024 is funded through the recent rights issue, including the readout of Verrica's phase ...
Through the completion of the equity issue, Lytix receives NOK50m before transaction costs.
Redeye briefly comments on Lytix’ share issue. We pause our coverage.
Lytix's partner Verrica fully recruited its phase II study in basal cell carcinoma in January, with a topline readout expect in H1 2024.
Redeye provides a first comment on the fourth quarter report and webinar, which had some significant new information.
Redeye comments on Lytix’ third results in 2023. In October, the first readout from the phase II trial of LTX-315 in combination with pembro...
Redeye comments on the first data from the ATLAS-IT-05 trial, a study of the oncolytic molecule LTX-315 in combination with checkpoint inhib...
Since our initiating coverage, Verrica presented promising results in BCC.
Redeye is encouraged by the full recruitment of 20 patients in ATLAS-IT-05, which we discuss in this note.
